Patents Assigned to Lytix Biopharma AS
-
Patent number: 11123398Abstract: The present invention provides a compound, preferably a peptide, having the following characteristics: a) consisting of 9 amino acids in a linear arrangement; b) of those 9 amino acids, 5 are cationic and 4 have a lipophilic R group; c) at least one of said 9 amino acids is a non-genetically coded amino acid (e.g. a modified derivative of a genetically coded amino acid); and optionally d) the lipophilic and cationic residues are arranged such that there are no more than two of either type of residue adjacent to one another; and further optionally e) the molecule comprises two pairs of adjacent cationic amino acids and one or two pairs of adjacent lipophilic residues; for use in the treatment of a tumour by combined, sequential or separate administration with a cytotoxic chemotherapeutic agent that inhibits immune tolerance, wherein the chemotherapeutic agent is administered at a sub-cytotoxic dose.Type: GrantFiled: November 4, 2015Date of Patent: September 21, 2021Assignee: LYTIX BIOPHARMA ASInventors: Liv Marie Eike, Ketil Camilio, Baldur Sveinbjornsson, Oystein Rekdal, John Sigurd Mjoen Svendsen
-
Patent number: 11083774Abstract: The present invention provides a compound, preferably a peptide, having the following characteristics: a) consisting of 9 amino acids in a linear arrangement; b) of those 9 amino acids, 5 are cationic and 4 have a lipophilic R group; c) at least one of said 9 amino acids is a non-genetically coded amino acid (e.g. a modified derivative of a genetically coded amino acid); and optionally d) the lipophilic and cationic residues are arranged such that there are no more than two of either type of residue adjacent to one another; and further optionally e) the molecule comprises two pairs of adjacent cationic amino acids and one or two pairs of adjacent lipophilic residues; for use in the treatment of a tumour by combined, sequential or separate administration with an immune checkpoint inhibitor. The present invention further provides pharmaceutical packs or compositions comprising these active agents and methods of treating a tumour comprising administration of these active agents.Type: GrantFiled: November 4, 2015Date of Patent: August 10, 2021Assignee: LYTIX BIOPHARMA ASInventors: Liv Marie Eike, Ketil Camilio, Baldur Sveinbjornsson, Laurence Zitvogel, Takahiro Yamazaki, Oystein Rekdal, John Sigurd Mjoen Svendsen
-
Patent number: 10231954Abstract: The present invention provides a compound of formula (I) wherein: Y represents a C or N atom which may be substituted or form a cyclic group with R?? but may not be a quaternary C atom; R? is —OR1, —CONH2, —CF3, F, —OH, —NO2, —CN or —OCOR1 in which R1, is C1-3 alkyl and each may be in the beta or gamma position; R? is C1-3 alkyl or H; and R?? is H or a group consisting of 1-12 non-hydrogen atoms and may be linear, branched and/or incorporate one or more cyclic groups, cyclic groups may be aromatic and/or heterocyclic and 2 or more cyclic groups may be linked or fused and each may be substituted; or a salt, hydrate or solvate of a compound of formula (I) for use in the treatment or prevention of a neurodegenerative disorder by inhibiting formation of neurofibrillary (tau) tangles and/or by inhibiting Dyrk 1A. The invention further relates to non-therapeutic uses of these compounds.Type: GrantFiled: February 4, 2015Date of Patent: March 19, 2019Assignee: LYTIX BIOPHARMA ASInventors: John S. Svendsen, Wenche Stensen, Frederick A. Leeson
-
Publication number: 20190038670Abstract: The present invention provides a method of generating a population of tumour-infiltrating T cells, said method comprising administering to a subject a positively charged amphipathic amino acid derivative, peptide or peptidomimetic which is able to lyse tumour cell membranes and then collecting a cellular sample from a tumour within said subject and separating T cells therefrom. The present invention further provides a method of generating a population of tumour-infiltrating T cells, said method comprising separating T cells from a cellular tumour sample taken from a subject treated with a positively charged amphipathic amino acid derivative, peptide or peptidomimetic which is able to lyse tumour cell membranes and optionally culturing said T cells. The present invention also provides the tumour-infiltrating T cells described above for use in treating tumour cells or preventing or reducing the growth, establishment, spread, or metastasis of a tumour.Type: ApplicationFiled: February 2, 2017Publication date: February 7, 2019Applicant: LYTIX BIOPHARMA ASInventors: Ketil André Camilio, Janne Merethe Nestvold, Baldur Sveinbjörnsson, Øystein Rekdal
-
Publication number: 20180264079Abstract: The present invention provides a compound, preferably a peptide, having the following characteristics: a) consisting of 9 amino acids in a linear arrangement; b) of those 9 amino acids, 5 are cationic and 4 have a lipophilic R group; c) at least one of said 9 amino acids is a non-genetically coded amino acid (e.g. a modified derivative of a genetically coded amino acid); and optionally d) the lipophilic and cationic residues are arranged such that there are no more than two of either type of residue adjacent to one another; and further optionally e) the molecule comprises two pairs of adjacent cationic amino acids and one or two pairs of adjacent lipophilic residues; for use in the treatment of a tumour by combined, sequential or separate administration with an immune checkpoint inhibitor. The present invention further provides pharmaceutical packs or compositions comprising these active agents and methods of treating a tumour comprising administration of these active agents.Type: ApplicationFiled: November 4, 2015Publication date: September 20, 2018Applicants: LYTIX BIOPHARMA AS, LYTIX BIOPHARMA ASInventors: Liv Marie Eike, Ketil Camilio, Baldur Sveinbjornsson, Laurence Zitvogel, Takahiro Yamazaki, Oystein Rekdal, John Sigurd Mjoen Svendsen
-
Publication number: 20170107250Abstract: The present invention relates to a compound of formula (I) AA-AA-AA-R1-R2 (I) wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; R1 is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group, which group may incorporate up to 2 heteroatoms selected from N, O and S; and R2 is an aliphatic moiety having 2-20 non-hydrogen atoms, said moiety being linear, branched or cyclic. The invention further relates to formulations containing these compounds, solid supports having these compounds attached thereto, the use of these compounds in therapy, particularly as antimicrobial, anti-tumour or anti-biofilm agents and non-therapeutic uses of these compounds, particularly their use in inhibiting biofilm formation or removing a biofilm.Type: ApplicationFiled: December 27, 2016Publication date: April 20, 2017Applicant: LYTIX BIOPHARMA ASInventors: Wenche Stensen, Frederick A. Leeson, Oystein Rekdal, John S. Svendsen
-
Patent number: 9556223Abstract: The present invention relates to a compound of formula (I) AA-AA-AA-R1—R2 (I) wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; R1 is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group, which group may incorporate up to 2 heteroatoms selected from N, O and S; and R2 is an aliphatic moiety having 2-20 non-hydrogen atoms, said moiety being linear, branched or cyclic. The invention further relates to formulations containing these compounds, solid supports having these compounds attached thereto, the use of these compounds in therapy, particularly as antimicrobial, anti-tumor or anti-biofilm agents and non-therapeutic uses of these compounds, particularly their use in inhibiting biofilm formation or removing a biofilm.Type: GrantFiled: October 2, 2009Date of Patent: January 31, 2017Assignee: LYTIX BIOPHARMA ASInventors: Wenche Stensen, Frederick Alan Leeson, Øystein Rekdal, John Sigurd Svendsen
-
Patent number: 9241968Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumor agents.Type: GrantFiled: September 11, 2009Date of Patent: January 26, 2016Assignee: Lytix Biopharma ASInventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
-
Patent number: 9212202Abstract: The present invention relates to a method of improving the resistance of a peptide or peptidomimetic to degradation by trypsin which comprises incorporating into said peptide or peptidomimetic a C-terminal capping group of formula (I): X—Y—Z (I) wherein X is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group which group may incorporate up to 2 heteroatoms selected from N, O and S; Y represents a group selected from —Ra—Rb—, —Ra—Rb—Rb,- and —Rb—Rb—Ra— wherein Ra is C, O, S or N, and Rb is C; each of Ra and Rb, may be substituted by C1-C4 alkyl groups or unsubstituted; and Z is a group comprising 1 to 3 cyclic groups each of 5 or 6 non-hydrogen atoms, 2 or more of the cyclic groups may be fused and one or more of the cyclic groups may be substituted; the Z. moiety incorporates a maximum of 15 non-hydrogen atoms; and wherein the bond between Y and Z is a covalent bond between Ra or Rb of Y and a non-hydrogen atom of one of the cyclic groups of Z.Type: GrantFiled: December 22, 2008Date of Patent: December 15, 2015Assignee: Lytix Biopharma ASInventors: Wenche Stensen, Oystein Rekdal, John Sigurd Svendsen
-
Patent number: 9115169Abstract: The invention provides a method of treating tumors by adminstering to a human or animal patient an effective amount of a molecule of 2 to 4 amino acids or equivalent subunits in length, which incorporates a bulky and lipophilic group comprising at least 13 non-hydrogen atoms and containing no more than 2 polar functional groups, in which the bulky and lipophilic group incorporates one or more closed rings of 5 or more non-hydrogen atoms, and in which the molecule further has at least two more cationic than anionic moieties.Type: GrantFiled: September 22, 2011Date of Patent: August 25, 2015Assignee: Lytix Biopharma ASInventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
-
Patent number: 9109048Abstract: The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoral agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumor growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject.Type: GrantFiled: August 14, 2012Date of Patent: August 18, 2015Assignee: LYTIX BIOPHARMA ASInventors: Liv Tone Eliassen, Gerd Berge, Baldur Sveinbjørnsson, John Sigurd Svendsen, Øystein Rekdal
-
Patent number: 9085608Abstract: The present invention relates to a peptide or peptidomimetic for use in the treatment of a biofilm-associated infection in a subject, wherein said peptide or peptidomimetic a) carries a net positive charge, —b) is 1 to 6 amino acids in length or is an equivalently sized peptidomimetic; and c) is amphipathic in nature, having one or more lipophilic groups, one of said lipophilic groups comprising at least 7 non-hydrogen atoms.Type: GrantFiled: October 2, 2009Date of Patent: July 21, 2015Assignee: LYTIX BIOPHARMA ASInventors: Wenche Stensen, Frederick Alan Leeson, Stig Olov Magnus Engqvist, Trond Flægstad, Øystein Rekdal, John Sigurd Svendsen
-
Patent number: 8809280Abstract: The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted ? amino acid, each of the substituting groups in the ? amino acid, which may be the same or different, comprises at least (7) non-hydrogen atoms, is lipophilic and has at least one cyclic group, one or more cyclic groups within a substituting group may be linked or fused to one or more cyclic groups within the other substituting group and where cyclic groups are fused in this way the combined total number of non-hydrogen atoms for the two substituting groups is at least (12), for use as a cytolytic therapeutic agent; as well as non therapeutic uses of these molecules and certain defined novel compounds from within this definition.Type: GrantFiled: November 2, 2010Date of Patent: August 19, 2014Assignee: Lytix Biopharma ASInventors: Morten Strom, Terkel Hansen, Martina Havelkova, Veronika Torfoss
-
Publication number: 20140037657Abstract: The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoral agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumor growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject.Type: ApplicationFiled: August 14, 2012Publication date: February 6, 2014Applicant: LYTIX BIOPHARMA ASInventors: Liv Tone Eliassen, Gerd Berge, Baldur Sveinbjornsson, John Sigurd Svendsen, Oystein Rekdal
-
Patent number: 8598114Abstract: The present invention relates to a compound of formula (I) AA-AA-AA-X—Y—Z wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; X is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group which group may incorporate up to 2 heteroatoms selected from N, O and S; Y represents a group selected from —Ra—Rb—, —Ra—Rb—Rb— and —Rb—Rb—Ra— wherein Ra is C, O, S or N, and Rb is C; each of Ra and Rb may be substituted by C1-C4 alkyl groups or unsubstituted; and Z is a group comprising 1 to 3 cyclic groups each of 5 or 6 non-hydrogen atoms, 2 or more of the cyclic groups may be fused and one or more of the cyclic groups may be substituted; the Z moiety incorporates a maximum of 15 non-hydrogen atoms; and wherein the bond between Y and Z is a covalent bond between Ra or Rb of Y and a non-hydrogen atom of one of the cyclic groups of Z.Type: GrantFiled: December 22, 2008Date of Patent: December 3, 2013Assignee: Lytix Biopharma ASInventors: Wenche Stensen, Bengt Erick Haug, Oystein Rekdal, John Sigurd Svendsen
-
Publication number: 20130035296Abstract: The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted ? amino acid, each of the substituting groups in the ? amino acid, which may be the same or different, comprises at least (7) non-hydrogen atoms, is lipophilic and has at least one cyclic group, one or more cyclic groups within a substituting group may be linked or fused to one or more cyclic groups within the other substituting group and where cyclic groups are fused in this way the combined total number of non-hydrogen atoms for the two substituting groups is at least (12), for use as a cytolytic therapeutic agent; as well as non therapeutic uses of these molecules and certain defined novel compounds from within this definition.Type: ApplicationFiled: November 2, 2010Publication date: February 7, 2013Applicant: LYTIX BIOPHARMA ASInventors: Morten Strom, Terkel Hansen, Martina Havelkova, Veronika Torfoss
-
Patent number: 8283315Abstract: The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them and their use as medicaments, particularly as antibacterions or antitumoral agents. In a preferred aspect, the invention provides the use of said peptides in a method of inducing adaptive immunity against tumor growth or establishment in a subject, as well as the use of other lytic agents in a method of inducing adaptive immunity in a subject.Type: GrantFiled: March 21, 2007Date of Patent: October 9, 2012Assignee: Lytix Biopharma ASInventors: Liv Tone Eliassen, Gerd Berge, Baldur Sveinbjørnsson, John Sigurd Svendsen, Øystein Rekdal
-
Publication number: 20120108520Abstract: The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics.Type: ApplicationFiled: September 22, 2011Publication date: May 3, 2012Applicant: LYTIX BIOPHARMA ASInventors: John Sigurd Svendsen, Bengt Erik Haug, Istvan Marko, Øystein Rekdal, Merete Linchausen Skar, Wenche Stensen, Morten Bøhmer Strøm
-
Patent number: 8143211Abstract: The present invention provides a cytotoxic 7 to 25-mer peptide with three or more cationic residues which has one or more non-generic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them, and their use as medicaments, particularly as antibacterial or antitumor agents.Type: GrantFiled: July 2, 2008Date of Patent: March 27, 2012Assignee: Lytix Biopharma ASInventors: John Sigurd Svendsen, Øystein Rekdal, Baldur Sveinbjørnsson, Lars Vorland
-
Publication number: 20110318364Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.Type: ApplicationFiled: September 11, 2009Publication date: December 29, 2011Applicant: LYTIX BIOPHARMA ASInventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal